COVID-19
Conditions
Brief summary
Children infected with COVID-19 are mostly asymptomatic. There is a dearth of data on the epidemiology of COVID-19 in the pediatric population. This is a prospective observational clinical study of pediatric surgical patients. COVID-19 rapid antigen testing will be performed on pediatric patients.
Detailed description
Children infected with COVID-19 are mostly asymptomatic or mildly symptomatic. Children may spread COVID-19 to the elderly, vulnerable patients and medical staff. There is a dearth of data on the epidemiology of COVID-19 in the pediatric surgical population. Rapid antigen detection tests for the diagnosis of COVID-19 are reliable, simple, fast, and inexpensive. This is a prospective observational clinical study. The study population will include all consenting pediatric surgical patients, aged 2-17 years. Informed consent will be obtained from each patient and the legal guardian who agree to participate in the study. Nasopharyngeal swab specimens will be collected from anesthetized pediatric patients. COVID-19 rapid antigen testing will be performed according to the equipment manufacturer's instructions. Data collection will include COVID-19 test result, nasal swab complication, patient demographics, surgical history, medical history, regular medications, COVID-19 symptoms, and COVID-19 exposure information. COVID-19 symptoms that will be recorded are cough, wheeze, nasal congestion, breathing difficulty, new loss of taste or smell, fever, chills, rigors, body aches, sore throat, nausea, and fatigue. COVID-19 exposure will be considered as being within 6 feet of a person with diagnosed COVID-19 infection in the previous 14 days.
Interventions
COVID-19 rapid antigen testing of nasal swab
Sponsors
Study design
Eligibility
Inclusion criteria
* surgical patients aged 2-17 years * informed consent for surgery * no COVID-19 diagnosis in previous 6 months * no history of nasal bleeding * no history of coagulopathy.
Exclusion criteria
* patient refusal of testing * difficulty in obtaining consent * COVID-19 diagnosis in recent 6 month * history of nasal bleeding * history of coagulopathy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antigen test positive result | 1 day | COVID-19 antigen test positive |
Countries
Canada